Thursday, 15 October 2026European Markets

ELECTROMAGNET GEO Stock Bullish By 15% At Session Start On Tuesday

Loading stream...

(VIANEWS) - Shares of ELECTROMAGNET GEO (Oslo Børs All-share Index_GI: EMGS.OL) jumped by a staggering 15.2% to kr4.25 at 10:26 EST on Tuesday, following the last session's upward trend. Oslo Børs All-share Index_GI is rising 0.12% to kr1,417.68, after five successive sessions in a row of losses. This seems, at the moment, a somewhat up trend trading session today.

About ELECTROMAGNET GEO

Electromagnetic Geoservices ASA, together with its subsidiaries, provides electromagnetic (EM) surveying services to the offshore oil and gas exploration industry. It is involved in the planning, acquisition, processing, modelling, interpretation, and integration of EM data. The company uses its patented EM survey method to find hydrocarbons in offshore reservoirs. It engages in the provision of controlled-source EM surveying and magneto telluric surveying; imaging and interpretation; rental of software and cluster; and training services. The company has operations in Europe, the Middle East, Africa, Norway, North and South America, Asia, and the Pacific Ocean. Electromagnetic Geoservices ASA was incorporated in 2002 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ELECTROMAGNET GEO has a trailing twelve months EPS of kr-1.492.

More news about ELECTROMAGNET GEO (EMGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com